John Christodouleas
@xristodouleas.bsky.social
Radiation Oncologist at PENN and Elekta Medical Affairs.
t.co/BBFJjqLdMS
GBM Rad Oncs: if 5 fx is proven non-inferior with respect to OS, does it win the day?
As a non-GBM doc, I’m puzzled why in 2025 this hasn’t been already investigated more broadly given the prognosis and prior work from Stanford.
@mrlconsortium.bsky.social
GBM Rad Oncs: if 5 fx is proven non-inferior with respect to OS, does it win the day?
As a non-GBM doc, I’m puzzled why in 2025 this hasn’t been already investigated more broadly given the prognosis and prior work from Stanford.
@mrlconsortium.bsky.social
June 23, 2025 at 2:54 PM
t.co/BBFJjqLdMS
GBM Rad Oncs: if 5 fx is proven non-inferior with respect to OS, does it win the day?
As a non-GBM doc, I’m puzzled why in 2025 this hasn’t been already investigated more broadly given the prognosis and prior work from Stanford.
@mrlconsortium.bsky.social
GBM Rad Oncs: if 5 fx is proven non-inferior with respect to OS, does it win the day?
As a non-GBM doc, I’m puzzled why in 2025 this hasn’t been already investigated more broadly given the prognosis and prior work from Stanford.
@mrlconsortium.bsky.social
For muscle-invasive bladder cancer, the Lancet Oncology paper by Zlotta et al is the best comparative effectiveness study of TMT versus RC. How can we use this study to communicate the risks of delayed cystectomy to patients? Peppin A et al provide an answer at GU ASCO 2025:
February 16, 2025 at 6:24 PM
For muscle-invasive bladder cancer, the Lancet Oncology paper by Zlotta et al is the best comparative effectiveness study of TMT versus RC. How can we use this study to communicate the risks of delayed cystectomy to patients? Peppin A et al provide an answer at GU ASCO 2025: